AR072428A1 - Derivados de pirimidin nucleotidos inhibidores de polimerasas del virus de la hepatitis c (vhc), composiciones farmaceuticas que los contienen y metodo para prepararlos. - Google Patents
Derivados de pirimidin nucleotidos inhibidores de polimerasas del virus de la hepatitis c (vhc), composiciones farmaceuticas que los contienen y metodo para prepararlos.Info
- Publication number
- AR072428A1 AR072428A1 ARP090102442A ARP090102442A AR072428A1 AR 072428 A1 AR072428 A1 AR 072428A1 AR P090102442 A ARP090102442 A AR P090102442A AR P090102442 A ARP090102442 A AR P090102442A AR 072428 A1 AR072428 A1 AR 072428A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- alkyl
- pirimidin
- nucleotid
- hcv
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
Abstract
Reivindicacion 1: Un compuesto de formula 1 incluyendo cualquiera de los estereoisomeros posibles, donde: R2 es hidrogeno o alquilo C1-4; R3 y R4 se seleccionan, independientemente, del grupo formado por hidrogeno, -C(=O)R5, y -C(=O)-CHR6-NH2; o R3 es hidrogeno y R4 es un éster de monofosfato, difosfato, o trifosfato; o R3 es H, -C(=O)CHR5, o -C(=O)CHR6-NH2 y R4 es un grupo de formula (2), cada R5 se selecciona, independientemente, del grupo formado por hidrogeno, alquilo C1-6, y cicloalquilo C3-7; R6 es hidrogeno o alquilo C1-6; R7 es fenilo, opcionalmente-sustituido con 1, 2 o 3 sustituyentes cada uno seleccionado independientemente entre halo, alquilo C1-6, alquenilo C3-6, alcoxi C1-6, hidroxi, y amino, o R7 es naftilo; o R7 es indolilo; R8 es hidrogeno, alquilo C1-6, bencilo; R8' es hidrogeno, alquilo C1-6, bencilo; o R8 y R8' junto con el átomo de carbono al cual están unidos forman cicloalquilo C3-7; R9 es alquilo C1-6, bencilo, o fenilo, donde dicho fenilo puede estar opcionalmente sustituido con 1, 2 o 3 sustituyentes cada uno seleccionado independientemente entre hidroxi, alcoxi C1-6, amino, mono- y dialquilamino C1-6, siempre que R2, R3 y R4 no sean todos hidrogeno; o sus sales o solvatos aceptables para uso farmacéutico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08159396 | 2008-07-01 | ||
EP08171005 | 2008-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR072428A1 true AR072428A1 (es) | 2010-08-25 |
Family
ID=41095413
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090102442A AR072428A1 (es) | 2008-07-01 | 2009-06-30 | Derivados de pirimidin nucleotidos inhibidores de polimerasas del virus de la hepatitis c (vhc), composiciones farmaceuticas que los contienen y metodo para prepararlos. |
Country Status (29)
Country | Link |
---|---|
US (1) | US8431588B2 (es) |
EP (1) | EP2141172B1 (es) |
JP (1) | JP5624029B2 (es) |
KR (1) | KR20110038683A (es) |
CN (2) | CN102083845B (es) |
AP (1) | AP2010005505A0 (es) |
AR (1) | AR072428A1 (es) |
AU (1) | AU2009266004B2 (es) |
BR (1) | BRPI0913643A2 (es) |
CA (1) | CA2729316A1 (es) |
CL (1) | CL2010001634A1 (es) |
CO (1) | CO6321255A2 (es) |
DK (1) | DK2141172T3 (es) |
EA (1) | EA022754B1 (es) |
EC (1) | ECSP10010725A (es) |
ES (1) | ES2396803T3 (es) |
HK (1) | HK1226080A1 (es) |
HR (1) | HRP20121068T1 (es) |
IL (1) | IL209932A (es) |
MX (1) | MX2010014493A (es) |
NI (1) | NI201000231A (es) |
PL (1) | PL2141172T3 (es) |
PT (1) | PT2141172E (es) |
SI (1) | SI2141172T1 (es) |
SV (1) | SV2010003779A (es) |
TW (1) | TW201012814A (es) |
UY (1) | UY31950A (es) |
WO (1) | WO2010000459A1 (es) |
ZA (1) | ZA201009294B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220018610A (ko) * | 2008-09-08 | 2022-02-15 | 사우디 아람코 테크놀로지스 컴퍼니 | 폴리카보네이트 폴리올 조성물 |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
TW201201815A (en) * | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
EP2658858A4 (en) | 2010-12-30 | 2014-06-25 | Enanta Pharm Inc | MACROCYCLIC INHIBITORS OF HEPATITIS C SERINE PROTEASE PHENANTHRIDINE |
WO2012092409A2 (en) | 2010-12-30 | 2012-07-05 | Enanta Phararmaceuticals, Inc | Macrocyclic hepatitis c serine protease inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
JP5845841B2 (ja) | 2011-11-18 | 2016-01-20 | 東芝ライテック株式会社 | 照明制御装置 |
EP2814816A2 (en) | 2012-02-14 | 2014-12-24 | University Of Georgia Research Foundation, Inc. | Spiro [2.4]heptanes for treatment of flaviviridae infections |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
RU2764767C2 (ru) | 2015-03-06 | 2022-01-21 | Атеа Фармасьютикалс, Инк. | β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-С-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ |
RU2590952C1 (ru) * | 2015-05-26 | 2016-07-10 | Вячеслав Энгельсович Семёнов | Средство гепатопротекторного действия |
US10711029B2 (en) | 2016-07-14 | 2020-07-14 | Atea Pharmaceuticals, Inc. | Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
PL3512863T3 (pl) | 2016-09-07 | 2022-04-04 | Atea Pharmaceuticals, Inc. | 2'-Podstawione-N6-podstawione nukleotydy purynowe do leczenia zakażeń wirusem RNA |
SG10202012214WA (en) | 2017-02-01 | 2021-01-28 | Atea Pharmaceuticals Inc | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus |
WO2019200005A1 (en) | 2018-04-10 | 2019-10-17 | Atea Pharmaceuticals, Inc. | Treatment of hcv infected patients with cirrhosis |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100360964B1 (ko) | 1992-12-29 | 2002-11-22 | 아보트 러보러터리즈 | 레트로바이러스성 프로테아제 억제 화합물의 중간체의제조방법 |
IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
IL111991A (en) * | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
GB0114286D0 (en) * | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
RS114004A (en) * | 2002-06-28 | 2007-02-05 | Idenix (Cayman) Limited, | Modified 2' and 3'-nucleoside produgs for treating flaviridae infections |
NZ542342A (en) * | 2003-04-25 | 2009-05-31 | Gilead Sciences Inc | Antiviral phosphonate analogs |
EP1794172B1 (en) * | 2004-08-23 | 2009-07-15 | F.Hoffmann-La Roche Ag | Antiviral 4'-azido-nucleosides |
CN101573370B (zh) | 2006-10-10 | 2013-09-11 | 美迪维尔公司 | Hcv核苷类抑制剂 |
-
2009
- 2009-06-30 TW TW098121932A patent/TW201012814A/zh unknown
- 2009-06-30 AR ARP090102442A patent/AR072428A1/es not_active Application Discontinuation
- 2009-06-30 UY UY0001031950A patent/UY31950A/es unknown
- 2009-07-01 KR KR1020117002345A patent/KR20110038683A/ko not_active Application Discontinuation
- 2009-07-01 US US12/999,263 patent/US8431588B2/en not_active Expired - Fee Related
- 2009-07-01 EP EP09008634A patent/EP2141172B1/en active Active
- 2009-07-01 BR BRPI0913643A patent/BRPI0913643A2/pt not_active IP Right Cessation
- 2009-07-01 DK DK09008634.9T patent/DK2141172T3/da active
- 2009-07-01 CN CN200980125579.1A patent/CN102083845B/zh not_active Expired - Fee Related
- 2009-07-01 CA CA2729316A patent/CA2729316A1/en not_active Abandoned
- 2009-07-01 AP AP2010005505A patent/AP2010005505A0/xx unknown
- 2009-07-01 PT PT90086349T patent/PT2141172E/pt unknown
- 2009-07-01 AU AU2009266004A patent/AU2009266004B2/en not_active Ceased
- 2009-07-01 WO PCT/EP2009/004748 patent/WO2010000459A1/en active Application Filing
- 2009-07-01 EA EA201170118A patent/EA022754B1/ru not_active IP Right Cessation
- 2009-07-01 SI SI200930467T patent/SI2141172T1/sl unknown
- 2009-07-01 CN CN201610033092.2A patent/CN105693794A/zh active Pending
- 2009-07-01 ES ES09008634T patent/ES2396803T3/es active Active
- 2009-07-01 JP JP2011515237A patent/JP5624029B2/ja not_active Expired - Fee Related
- 2009-07-01 MX MX2010014493A patent/MX2010014493A/es active IP Right Grant
- 2009-07-01 PL PL09008634T patent/PL2141172T3/pl unknown
-
2010
- 2010-12-12 IL IL209932A patent/IL209932A/en not_active IP Right Cessation
- 2010-12-22 SV SV2010003779A patent/SV2010003779A/es not_active Application Discontinuation
- 2010-12-23 CO CO10161808A patent/CO6321255A2/es not_active Application Discontinuation
- 2010-12-23 ZA ZA2010/09294A patent/ZA201009294B/en unknown
- 2010-12-23 NI NI201000231A patent/NI201000231A/es unknown
- 2010-12-29 EC EC2010010725A patent/ECSP10010725A/es unknown
- 2010-12-30 CL CL2010001634A patent/CL2010001634A1/es unknown
-
2012
- 2012-12-27 HR HRP20121068AT patent/HRP20121068T1/hr unknown
-
2016
- 2016-12-15 HK HK16114266A patent/HK1226080A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR072428A1 (es) | Derivados de pirimidin nucleotidos inhibidores de polimerasas del virus de la hepatitis c (vhc), composiciones farmaceuticas que los contienen y metodo para prepararlos. | |
AR074504A1 (es) | Nucleotidos uracil ciclopropilicos | |
AR076579A1 (es) | Espironucleosidos uracilicos oxetanicos, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del virus de la hepatitis c (vhc). | |
AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
CO6160296A2 (es) | Derivados de acido benzoazepin-oxi-acetico como agonistas de receptores activados por proliferador de peroxisona delta usados para incrementar la lipoproteina de alta densidad-colesterol-colesterol reducir la lipoproteina de baja densidad-colesterol | |
AR113818A2 (es) | Pirazolo-quinazolinas como inhibidores de proteína quinasa | |
AR069435A1 (es) | Derivados de aminotiazol, proceso para la obtencion de los mismos, composiciones farmaceuticas y su uso como inhibidores de la fbpasa | |
AR059184A1 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica | |
UY29702A1 (es) | Inhibidores macrocíclicos del virus de hepatitis c | |
AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
AR055150A1 (es) | Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso | |
AR055360A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
AR054081A1 (es) | Derivados de pirimidina, procesos de obtencion y composiciones farmaceuticas | |
AR057980A1 (es) | Derivados de la 1- amino-ftalazina sustituida, su preparacion y composicion farmaceutica | |
RU2008102993A (ru) | НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
AR076900A1 (es) | Derivados heterociclicos nitrogenados utiles como agentes antivirales, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del vhc | |
AR089408A1 (es) | Nucleosidos sustituidos, nucleotidos y analogos de los mismos para ser empleados en el tratamiento de enfermedades virales | |
AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
AR087919A1 (es) | Heterociclos biciclicos como inhibidores de irak4 | |
CL2012000999A1 (es) | Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina. | |
EA200970493A1 (ru) | Макроциклические ингибиторы вируса гепатита с | |
CU23706B7 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
AR060903A1 (es) | Derivados de 1,2,3,4-tetrahidro-quinolina como inhibidores de cetp | |
AR074862A1 (es) | Derivados de heterociclo biciclicos y sus metodos de uso | |
CU20090048A7 (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |